BioCentury | Jun 7, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: May 2018

New Therapeutic Targets and Biomarkers: May 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during May 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | May 15, 2018
Distillery Therapeutics

Ophthalmic disease

INDICATION: Retinitis Mouse studies suggest promoting expression of the proteasome subunits PSME1 or PSMD11 could help treat retinitis pigmentosa. In a mouse model of the disease, overexpression of PSME1 or PSMD11 increased photoreceptor survival and...
BioCentury | May 8, 2018
Translation in Brief

Proteasome overload

Researchers at Duke University School of Medicine have found that activating proteasomes in the retina could treat degenerative retinal diseases driven by protein misfolding and expect the approach could apply to other neurodegenerative disorders. Vadim...
BioCentury | Sep 1, 2016
Distillery Therapeutics

Therapeutics: Proteasome activator subunit 3 (PSME3)

...Cancer INDICATION: Colorectal cancer Cell culture and mouse studies suggest combining inhibitors of PSME3 and glycosis...
...alone. Next steps could include identifying and testing PSME3 inhibitors in colorectal cancer models. TARGET/MARKER/PATHWAY: Proteasome activator subunit 3 (PSME3)...
BioCentury | Oct 10, 2013
Distillery Therapeutics

Indication: Hepatic disease

...contact information Hepatic disease Liver disease Proteasome activator subunit 3 (PSME3) Mouse studies suggest inhibition of the proteasome activator PSME3...
...could help treat and prevent liver steatosis. In mice fed a high-fat diet, deletion of Psme3...
...prevented lipid accumulation and onset of liver steatosis. Next steps include analyzing the effects of Psme3...
Items per page:
1 - 5 of 5